tirzepatide approved for teens Kids weight loss drugs! GLP-1 Medications Are Becoming More
Description
No concerns
It has real potential here in what is going to be the transformative blockbuster new indication in obesity, which is post-GLP-1 weight maintenance. Clinically testing the post-GLP-1 reality REMAIN-1 is a 45-patient, prospective, randomized, double-blind, sham-controlled study enrolling people with obesity but without type 2 diabetes
Some people lose 15 pounds in the first month
Review MEDVi enrollment and program access information
My appetite remained decreased, and I still occasionally felt unwell
Whether its inclusion provides meaningful advantage over formulations containing only tirzepatide and B12 remains uncertain
